Literature DB >> 7438688

Anticholinergic effects and plasma desipramine levels.

M V Rudorfer, R C Young.   

Abstract

Anticholinergic effects of the tricyclic antidepressant desipramine were studied in 12 outpatients. Objective measurements of salivation and pulse rate and subjective ratings of mouth dryness and palpitations were made before and during treatment with desipramine at a final daily dosage of 150 mg. There were significant changes after 3 wk of treatment in all parameters except ratings of palpitation. Subjects with moderate or high plasma desipramine levels had more suppression of salivation than those with low levels. Changes in salivation and pulse did not correlate, nor did they correlate with subjective reports.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438688     DOI: 10.1038/clpt.1980.224

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Plasma levels and clinical response with imipramine in a study comparing efficacy with mianserin and nomifensine.

Authors:  S A Montgomery; D Roy; S Wynne-Willson; C Robinson; D B Montgomery
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

Review 2.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

3.  Comparison of the effects of chronic administration of ciclazindol and desipramine on pupillary responses to tyramine, methoxamine and pilocarpine in healthy volunteers.

Authors:  F A Kerr; E Szabadi
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

Review 4.  Metabolism of tricyclic antidepressants.

Authors:  M V Rudorfer; W Z Potter
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 5.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.